GE HealthCare Forecasts 2026 Adjusted EPS of $4.95-$5.05 and Advances SOFIE Biosciences Acquisition
GE HealthCare (GEHC) reported strong third-quarter performance, characterized by top-line growth and margin expansion across all business segments. CEO Peter Arduini noted that robust demand for advanced imaging solutions and pharmaceutical diagnostics has bolstered order volumes, book-to-bill ratios, and the company's overall backlog. Looking ahead, the company provided a 2026 adjusted earnings per share (EPS) guidance range of $4.95 to $5.05. Additionally, GE HealthCare is progressing with its strategic acquisition of SOFIE Biosciences, aimed at strengthening its position in the pharmaceutical diagnostics market.
Tickers: $GEHC
Topics: earnings report margin expansion order backlog revenue growth